New treatment options for immune-mediated hematological disorders

被引：7

作者：

Dierickx, Daan ^{[1
]}

De Rycke, Anja ^{[2
]}

Vanderschueren, Steven ^{[2
]}

Delannoy, Andre ^{[3
]}

机构：

[1] Univ Hosp Gasthuisberg, Dept Hematol, Louvain, Belgium

[2] Univ Hosp Gasthuisberg, Dept Internal Med, Louvain, Belgium

[3] Hop Jolimont, Dept Hematol, Haine St Paul, Belgium

来源：

EUROPEAN JOURNAL OF INTERNAL MEDICINE | 2008年 / 19卷 / 08期

关键词：

Auto-immune hemolytic anemia; Idiopathic thrombocytopenic purpura; Thrombotic thrombocytopenic purpura; Rituximab; Thrombopoietic growth factors;

D O I：

10.1016/j.ejim.2007.08.012

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

In recent years, there has been a tremendous increase in the number of clinical studies with monoclonal antibodies and small molecules in the treatment of hematological malignancies. Clinical observations have shown that some of these molecules may also aid in the treatment of immune-mediated hematological disorders. Moreover, immunotherapy has become an important treatment cornerstone in other, non-hematological, auto-immune diseases. This paper reviews the current state of the use of these new molecules in the treatment of the most frequently encountered immune-mediated hematological disorders: auto-immune hemolytic anemia (AIHA), idiopathic thrombocytopenic purpura (ITP), and thrombotic thrombocytopenic purpura (TTP). (C) 2008 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.

引用

页码：579 / 586

页数：8

共 75 条

[1] Rituximab for treatment of refractory/relapsing thrombotic thrombocytopenic purpura (TTP) [J].

Ahmad, A ;

Aggarwal, A ;

Sharma, D ;

Dave, HP ;

Kinsella, V ;

Rick, ME ;

Schechter, GP .

AMERICAN JOURNAL OF HEMATOLOGY, 2004, 77 (02) :171-176

[2]

AHN ER, 2005, BLOOD, V106, P4006

[3] Systematic review: Efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura [J].

Arnold, Donald M. ;

Dentali, Francesco ;

Crowther, Mark A. ;

Meyer, Ralph M. ;

Cook, Richard J. ;

Sigouin, Christopher ;

Fraser, Graeme A. ;

Lim, Wendy ;

Kelton, John G. .

ANNALS OF INTERNAL MEDICINE, 2007, 146 (01) :25-W5

[4]

AU WY, 2007, BR J HAEMATOL 0403

[5]

Beardsley Diana S, 2006, Hematology Am Soc Hematol Educ Program, P402

[6] Prospective phase 1/2 study of rituximab in childhood and adolescent chronic immune thrombocytopenic purpura [J].

Bennett, CM ;

Rogers, ZR ;

Kinnamon, DD ;

Bussel, JB ;

Mahoney, DH ;

Abshire, TC ;

Sawaf, H ;

Moore, TB ;

Loh, ML ;

Glader, BE ;

McCarthy, MC ;

Mueller, BU ;

Olson, TA ;

Lorenzana, AN ;

Mentzer, WC ;

Buchanan, GR ;

Feldman, HA ;

Neufeld, EJ .

BLOOD, 2006, 107 (07) :2639-2642

[7] Rituximab for primary chronic cold agglutinin disease: a prospective study of 37 courses of therapy in 27 patients [J].

Berentsen, S ;

Ulvestad, E ;

Gjertsen, BT ;

Hjorth-Hansen, H ;

Langholm, R ;

Knutsen, H ;

Ghanima, W ;

Shammas, FV ;

Tjonnfjord, GE .

BLOOD, 2004, 103 (08) :2925-2928

[8] A classification of hemolytic uremic syndrome and thrombotic thrombocytopenic purpura and related disorders [J].

Besbas, N. ;

Karpman, D. ;

Landau, D. ;

Loirat, C. ;

Proesmans, W. ;

Remuzzi, G. ;

Rizzoni, G. ;

Taylor, C. M. ;

Van de Kar, N. ;

Zimmerhackl, L. B. .

KIDNEY INTERNATIONAL, 2006, 70 (03) :423-431

[9] Rituximab chimeric anti-CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura [J].

Brændstrup, P ;

Bjerrum, OW ;

Nielsen, OJ ;

Jensen, BA ;

Clausen, NT ;

Hansen, PB ;

Andersen, I ;

Schmidt, K ;

Andersen, TM ;

Peterslund, NA ;

Birgens, HS ;

Plesner, T ;

Pedersen, BB ;

Hasselbalch, HC .

AMERICAN JOURNAL OF HEMATOLOGY, 2005, 78 (04) :275-280

[10] Treatment of immune thrombocytopenic purpura in adults [J].

Bussel, James .

SEMINARS IN HEMATOLOGY, 2006, 43 (03) :S3-S10

← 1 2 3 4 5 6 7 8 →